Company Name, Ticker, Customers, else..

Worst Performing Stocks In Major Pharmaceutical Preparations Industry During The Last 30 Days

1 Day

Week

Current Month of April

30 Days

Current Quarter Q2 of 2025

90 Days

Ytd

12 Months

Shares are down by -3.26% on average, in Major Pharmaceutical Preparations Industry during the last 30 days.

Here are the Worst performing stocks in Major Pharmaceutical Preparations Industry.

VINC

$0.0575

$-0.5091

-89.85%
Last 30 Days

VINC

$0.0575

$-0.5091

-89.85%

Vincerx Pharma Inc

Vincerx Pharma Inc shares declined -89.85% during the last 30 days.

Vincerx Pharma Inc*s business model is focused on developing and commercializing novel small molecule drugs for the treatment of cancer. They aim to leverage their scientific expertise and collaborations to identify and advance promising drug candidates, ultimately providing innovative therapies to patients in need.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.109 mill.	$ - mill.	$ -30.074 mill.	2 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.109 mill.	$ - mill.	$ -30.074 mill.
Employees	Shares Outstanding	P/E
12	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

OCEA

$0.0085

$-0.0695

-89.10%
Last 30 Days

OCEA

$0.0085

$-0.0695

-89.10%

Ocean Biomedical Inc

Ocean Biomedical Inc shares went down -89.10% during the last 30 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.237 mill.	$ - mill.	$ 78.367 mill.	28 mill.	0.01	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.237 mill.	$ - mill.	$ 78.367 mill.
Employees	Shares Outstanding	P/E
22	28 mill.	0.01
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

VRPX

$0.246

$-1.2340

-83.38%
Last 30 Days

VRPX

$0.246

$-1.2340

-83.38%

Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Inc stock dropped -83.38% during the last 30 days.

Virpax Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative non-opioid products to address the unmet needs in pain management. Their business model revolves around research, development, and commercialization of these non-opioid solutions to provide effective and safe pain relief options for patients.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.045 mill.	$ - mill.	$ -12.067 mill.	4 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.045 mill.	$ - mill.	$ -12.067 mill.
Employees	Shares Outstanding	P/E
5	4 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

IBIO

$0.919

$-3.4910

-79.16%
Last 30 Days

IBIO

$0.919

$-3.4910

-79.16%

Ibio inc

Ibio Inc shares dropped -79.16% during the last 30 days.

Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 8.392 mill.	$ 0.375 mill.	$ -20.220 mill.	9 mill.	-	Y/Y 300.00 %

Market Cap.	Revenues TTM	Net Income TTM
$ 8.392 mill.	$ 0.375 mill.	$ -20.220 mill.
Employees	Shares Outstanding	P/E
14	9 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 300.00 %	MRQ Y/Y - %

SCPX

$0.045

$-0.1120

-71.34%
Last 30 Days

SCPX

$0.045

$-0.1120

-71.34%

Scorpius Holdings inc

Scorpius Holdings Inc stock declined -71.34% during the last 30 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.318 mill.	$ 5.196 mill.	$ -24.487 mill.	7 mill.	-	Y/Y 27.55 %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.318 mill.	$ 5.196 mill.	$ -24.487 mill.
Employees	Shares Outstanding	P/E
-	7 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 27.55 %	MRQ Y/Y - %

PTN

$0.207

$-0.4930

-70.43%
Last 30 Days

PTN

$0.207

$-0.4930

-70.43%

Palatin Technologies Inc

Palatin Technologies Inc stock dropped -70.43% during the last 30 days.

Palatin Technologies Inc has a business model focused on developing and commercializing innovative medicines in the field of reproductive healthcare and sexual dysfunction. The company*s revenue streams primarily come from partnerships, licensing agreements, and product sales.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 4.271 mill.	$ - mill.	$ -26.270 mill.	21 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 4.271 mill.	$ - mill.	$ -26.270 mill.
Employees	Shares Outstanding	P/E
11	21 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

GRI

$1.82

$-4.0500

-68.99%
Last 30 Days

GRI

$1.82

$-4.0500

-68.99%

Gri Bio Inc

Gri Bio Inc shares went down -68.99% during the last 30 days.

Gri Bio Inc*s business model focuses on providing innovative biotechnology solutions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.020 mill.	$ - mill.	$ -8.207 mill.	0 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.020 mill.	$ - mill.	$ -8.207 mill.
Employees	Shares Outstanding	P/E
-	0 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ADTX

$2.3

$-3.8650

-62.69%
Last 30 Days

ADTX

$2.3

$-3.8650

-62.69%

Aditxt Inc

Aditxt Inc stock went down -62.69% during the last 30 days.

Aditxt Inc operates on a business model that focuses on developing and commercializing technologies used in the field of biotechnology and personalized medicine. They leverage their expertise in genomics and diagnostics to offer innovative solutions that enable individuals to better understand and manage their health. Through their products and services, Aditxt aims to deliver personalized diagnostics and immune monitoring platforms to empower people in making informed decisions about their well-being.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.017 mill.	$ 0.469 mill.	$ -37.920 mill.	0 mill.	-	Y/Y -79.73 %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.017 mill.	$ 0.469 mill.	$ -37.920 mill.
Employees	Shares Outstanding	P/E
31	0 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -79.73 %	MRQ Y/Y - %

SPRB

$0.1298

$-0.1877

-59.12%
Last 30 Days

SPRB

$0.1298

$-0.1877

-59.12%

Spruce Biosciences Inc

Spruce Biosciences Inc stock dropped -59.12% during the last 30 days.

Spruce Biosciences Inc*s business model focuses on developing and commercializing novel therapies for rare endocrine disorders.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 5.336 mill.	$ 4.911 mill.	$ -53.036 mill.	41 mill.	-	Y/Y -75.86 %

Market Cap.	Revenues TTM	Net Income TTM
$ 5.336 mill.	$ 4.911 mill.	$ -53.036 mill.
Employees	Shares Outstanding	P/E
33	41 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -75.86 %	MRQ Y/Y - %

ALDX

$2.66

$-3.6000

-57.51%
Last 30 Days

ALDX

$2.66

$-3.6000

-57.51%

Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc stock went down -57.51% during the last 30 days.

Aldeyra Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative therapies for rare diseases associated with immune-mediated conditions using their proprietary compounds and technology.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 158.048 mill.	$ - mill.	$ -55.851 mill.	59 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 158.048 mill.	$ - mill.	$ -55.851 mill.
Employees	Shares Outstanding	P/E
201	59 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

RLYB

$0.3033

$-0.4017

-56.98%
Last 30 Days

RLYB

$0.3033

$-0.4017

-56.98%

Rallybio Corporation

Rallybio Corporation shares declined -56.98% during the last 30 days.

Rallybio Corporation operates on a business model focused on developing transformative therapies for patients with severe and rare diseases. Their approach involves collaborating with leading academic institutions, leveraging breakthrough scientific discoveries, and utilizing advanced technologies to accelerate the development of novel treatments. Through strategic partnerships, Rallybio aims to bring these innovative therapies to market and improve the lives of individuals suffering from unmet medical needs.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 13.175 mill.	$ 0.600 mill.	$ -57.775 mill.	43 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 13.175 mill.	$ 0.600 mill.	$ -57.775 mill.
Employees	Shares Outstanding	P/E
-	43 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ELAB

$2.26

$-2.6200

-53.69%
Last 30 Days

ELAB

$2.26

$-2.6200

-53.69%

Elevai Labs Inc

Elevai Labs Inc shares dropped -53.69% during the last 30 days.

Elevai Labs Inc operates on a subscription-based model, providing users with access to their proprietary software platform that utilizes artificial intelligence technology. The platform is designed to assist businesses in automating mundane and repetitive tasks, improving operational efficiency. Elevai Labs generates revenue through monthly or annual fees charged to their customers based on the level of usage.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 7.154 mill.	$ 555.787 mill.	$ -809.823 mill.	3 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 7.154 mill.	$ 555.787 mill.	$ -809.823 mill.
Employees	Shares Outstanding	P/E
-	3 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

CAMP

$2.05

$-2.3700

-53.62%
Last 30 Days

CAMP

$2.05

$-2.3700

-53.62%

Camp4 Therapeutics Corporation

Camp4 Therapeutics Corporation stock dropped -53.62% during the last 30 days.

Calamp Corp is a technology company that specializes in providing wireless communication solutions and services. They offer a wide range of products, including telematics devices, software platforms, and mobile resource management solutions, catering to various industries such as transportation, logistics, and industrial sectors.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 9.617 mill.	$ 115.570 mill.	$ -141.020 mill.	5 mill.	-	Y/Y -99.08 %

Market Cap.	Revenues TTM	Net Income TTM
$ 9.617 mill.	$ 115.570 mill.	$ -141.020 mill.
Employees	Shares Outstanding	P/E
333	5 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -99.08 %	MRQ Y/Y - %

HEPA

$0.2875

$-0.3225

-52.87%
Last 30 Days

HEPA

$0.2875

$-0.3225

-52.87%

Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc shares declined -52.87% during the last 30 days.

Hepion Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company, focused on the development of targeted therapies for liver diseases including non-alcoholic steatohepatitis (NASH). The company*s business model revolves around developing innovative drug candidates, conducting clinical trials, and ultimately bringing effective liver disease treatments to market.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.035 mill.	$ - mill.	$ -13.192 mill.	0 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.035 mill.	$ - mill.	$ -13.192 mill.
Employees	Shares Outstanding	P/E
20	0 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PTPI

$0.054

$-0.0570

-51.35%
Last 30 Days

PTPI

$0.054

$-0.0570

-51.35%

Petros Pharmaceuticals inc

Petros Pharmaceuticals Inc stock declined -51.35% during the last 30 days.

Petros Pharmaceuticals Inc is a pharmaceutical company that operates on a business model focused on the research, development, and commercialization of innovative drugs and therapeutics. They strive to bring new solutions to market by leveraging their expertise in various therapeutic areas, ultimately aiming to improve patient outcomes and well-being.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.531 mill.	$ 4.387 mill.	$ -23.037 mill.	10 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.531 mill.	$ 4.387 mill.	$ -23.037 mill.
Employees	Shares Outstanding	P/E
-	10 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

LSB

$1.22

$-1.2809

-51.22%
Last 30 Days

LSB

$1.22

$-1.2809

-51.22%

Lakeshore Biopharma Co Ltd

Lakeshore Biopharma Co Ltd shares declined -51.22% during the last 30 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 13.045 mill.	$ 80.820 mill.	$ -61.094 mill.	11 mill.	-	Y/Y -19.18 %

Market Cap.	Revenues TTM	Net Income TTM
$ 13.045 mill.	$ 80.820 mill.	$ -61.094 mill.
Employees	Shares Outstanding	P/E
-	11 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -19.18 %	MRQ Y/Y - %

KALA

$3.18

$-3.1400

-49.68%
Last 30 Days

KALA

$3.18

$-3.1400

-49.68%

Kala Bio inc

Kala Bio Inc stock went down -49.68% during the last 30 days.

Kala Pharmaceuticals Inc operates on a business model that revolves around the development and commercialization of innovative ophthalmic therapeutics to address unmet needs in eye care. Their approach focuses on utilizing their proprietary mucus-penetrating particle (MPP) technology to enhance drug delivery and improve patient outcomes. By leveraging partnerships and collaborations with industry stakeholders, Kala Pharmaceuticals aims to bring novel therapies to market and improve the standard of care for various eye diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 12.066 mill.	$ - mill.	$ -38.511 mill.	4 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 12.066 mill.	$ - mill.	$ -38.511 mill.
Employees	Shares Outstanding	P/E
38	4 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

NCNA

$0.5501

$-0.5199

-48.59%
Last 30 Days

NCNA

$0.5501

$-0.5199

-48.59%

Nucana Plc

Nucana Plc stock declined -48.59% during the last 30 days.

Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 28.680 mill.	$ - mill.	$ -27.632 mill.	52 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 28.680 mill.	$ - mill.	$ -27.632 mill.
Employees	Shares Outstanding	P/E
18	52 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

DRMA

$0.739

$-0.6810

-47.96%
Last 30 Days

DRMA

$0.739

$-0.6810

-47.96%

Dermata Therapeutics Inc

Dermata Therapeutics Inc shares declined -47.96% during the last 30 days.

Dermata Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing dermatology and skin care products, focusing on innovative treatments for various skin conditions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.131 mill.	$ - mill.	$ -12.287 mill.	2 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.131 mill.	$ - mill.	$ -12.287 mill.
Employees	Shares Outstanding	P/E
11	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

MTVA

$0.8226

$-0.7374

-47.27%
Last 30 Days

MTVA

$0.8226

$-0.7374

-47.27%

Metavia Inc

Metavia Inc shares declined -47.27% during the last 30 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 6.376 mill.	$ - mill.	$ -22.419 mill.	8 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 6.376 mill.	$ - mill.	$ -22.419 mill.
Employees	Shares Outstanding	P/E
11	8 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

APVO

$0.6748

$-0.5752

-46.02%
Last 30 Days

APVO

$0.6748

$-0.5752

-46.02%

Aptevo Therapeutics Inc

Aptevo Therapeutics Inc shares dropped -46.02% during the last 30 days.

Aptevo Therapeutics Inc operates as a biotechnology company that focuses on the development of novel oncology and hematology therapeutics. The company primarily generates revenue through the sale of its products and potential collaborations with other pharmaceutical companies.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.186 mill.	$ - mill.	$ -24.130 mill.	0 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.186 mill.	$ - mill.	$ -24.130 mill.
Employees	Shares Outstanding	P/E
37	0 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

AVTX

$4.78

$-3.9500

-45.25%
Last 30 Days

AVTX

$4.78

$-3.9500

-45.25%

Avalo Therapeutics inc

Avalo Therapeutics Inc shares went down -45.25% during the last 30 days.

Avalo Therapeutics Inc is a biotechnology company that focuses on developing novel cancer therapies. Their business model revolves around discovering and advancing targeted therapeutics using their proprietary platform technology. They aim to bring innovative treatments to patients by employing a combination of scientific expertise, strategic collaborations, and clinical development.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 8.030 mill.	$ 0.441 mill.	$ -35.129 mill.	2 mill.	-	Y/Y -66.32 %

Market Cap.	Revenues TTM	Net Income TTM
$ 8.030 mill.	$ 0.441 mill.	$ -35.129 mill.
Employees	Shares Outstanding	P/E
44	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -66.32 %	MRQ Y/Y - %

OKUR

$2.6

$-2.0900

-44.56%
Last 30 Days

OKUR

$2.6

$-2.0900

-44.56%

Onkure Therapeutics Inc

Onkure Therapeutics Inc stock declined -44.56% during the last 30 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 8.963 mill.	$ 1.713 mill.	$ -52.673 mill.	3 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 8.963 mill.	$ 1.713 mill.	$ -52.673 mill.
Employees	Shares Outstanding	P/E
10	3 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

MIST

$1.28

$-0.9700

-43.11%
Last 30 Days

MIST

$1.28

$-0.9700

-43.11%

Milestone Pharmaceuticals inc

Milestone Pharmaceuticals Inc stock declined -43.11% during the last 30 days.

Milestone Pharmaceuticals Inc. is a pharmaceutical company that focuses on developing and commercializing innovative therapies for cardiovascular diseases. Their business model revolves around identifying unmet medical needs in the cardiovascular space and leveraging their expertise in drug development to create novel treatments. By conducting rigorous research, clinical trials, and collaborations, Milestone Pharmaceuticals aims to bring effective and safe medications to market, positively impacting patients* lives.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 79.320 mill.	$ - mill.	$ -41.519 mill.	62 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 79.320 mill.	$ - mill.	$ -41.519 mill.
Employees	Shares Outstanding	P/E
33	62 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

HCWB

$6.9

$-5.2000

-42.98%
Last 30 Days

HCWB

$6.9

$-5.2000

-42.98%

Hcw Biologics Inc

Hcw Biologics Inc stock dropped -42.98% during the last 30 days.

HCW Biologics Inc is a biotechnology company that operates on a business model focused on the research, development, and commercialization of biologic therapies. The company primarily focuses on developing and manufacturing novel biological products for various medical conditions. Their business model involves collaboration with industry partners, conducting clinical trials, and securing regulatory approvals for the commercialization of their biologic therapies.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 269.045 mill.	$ 2.567 mill.	$ -30.024 mill.	39 mill.	-	Y/Y -62.13 %

Market Cap.	Revenues TTM	Net Income TTM
$ 269.045 mill.	$ 2.567 mill.	$ -30.024 mill.
Employees	Shares Outstanding	P/E
-	39 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -62.13 %	MRQ Y/Y - %

ESPR

$0.92

$-0.6900

-42.86%
Last 30 Days

ESPR

$0.92

$-0.6900

-42.86%

Esperion Therapeutics inc

Esperion Therapeutics Inc shares declined -42.86% during the last 30 days.

Esperion Therapeutics Inc*s business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 170.019 mill.	$ 332.314 mill.	$ -51.745 mill.	185 mill.	-	Y/Y 114.30 %

Market Cap.	Revenues TTM	Net Income TTM
$ 170.019 mill.	$ 332.314 mill.	$ -51.745 mill.
Employees	Shares Outstanding	P/E
72	185 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 114.30 %	MRQ Y/Y - %

RENB

$0.3732

$-0.2763

-42.54%
Last 30 Days

RENB

$0.3732

$-0.2763

-42.54%

Renovaro Inc

Renovaro Inc stock declined -42.54% during the last 30 days.

Renovaro Biosciences Inc is a biotechnology company that focuses on developing innovative therapies and technologies for regenerative medicine. Their business model involves conducting research and development, and partnering with pharmaceutical companies to bring their products to the market.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 60.393 mill.	$ - mill.	$ -126.186 mill.	162 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 60.393 mill.	$ - mill.	$ -126.186 mill.
Employees	Shares Outstanding	P/E
-	162 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

CTNM

$4.41

$-3.0400

-40.81%
Last 30 Days

CTNM

$4.41

$-3.0400

-40.81%

Contineum Therapeutics Inc

Contineum Therapeutics Inc stock dropped -40.81% during the last 30 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 85.485 mill.	$ - mill.	$ -42.258 mill.	19 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 85.485 mill.	$ - mill.	$ -42.258 mill.
Employees	Shares Outstanding	P/E
10	19 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SCNX

$0.99

$-0.6600

-40.00%
Last 30 Days

SCNX

$0.99

$-0.6600

-40.00%

Scienture Holdings Inc

Scienture Holdings Inc stock dropped -40.00% during the last 30 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 3.619 mill.	$ 0.137 mill.	$ 9.066 mill.	4 mill.	0.07	Y/Y -94.90 %

Market Cap.	Revenues TTM	Net Income TTM
$ 3.619 mill.	$ 0.137 mill.	$ 9.066 mill.
Employees	Shares Outstanding	P/E
-	4 mill.	0.07
Revenue Growth	Income Growth
MRQ Y/Y -94.90 %	MRQ Y/Y - %

TRAW

$1.55

$-1.0200

-39.69%
Last 30 Days

TRAW

$1.55

$-1.0200

-39.69%

Traws Pharma inc

Traws Pharma Inc stock declined -39.69% during the last 30 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.490 mill.	$ 0.227 mill.	$ -22.447 mill.	1 mill.	-	Y/Y 1.79 %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.490 mill.	$ 0.227 mill.	$ -22.447 mill.
Employees	Shares Outstanding	P/E
-	1 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 1.79 %	MRQ Y/Y - %

PCSA

$0.2372

$-0.1528

-39.18%
Last 30 Days

PCSA

$0.2372

$-0.1528

-39.18%

Processa Pharmaceuticals Inc

Processa Pharmaceuticals Inc stock went down -39.18% during the last 30 days.

Processa Pharmaceuticals Inc is a biopharmaceutical company that operates by developing and commercializing innovative drug candidates for various medical conditions. They focus on advancing treatments through clinical trials, obtaining regulatory approvals, and partnering with other healthcare organizations for distribution and marketing.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.726 mill.	$ - mill.	$ -11.850 mill.	3 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.726 mill.	$ - mill.	$ -11.850 mill.
Employees	Shares Outstanding	P/E
12	3 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

IRWD

$0.8885

$-0.5715

-39.14%
Last 30 Days

IRWD

$0.8885

$-0.5715

-39.14%

Ironwood Pharmaceuticals inc

Ironwood Pharmaceuticals Inc stock went down -39.14% during the last 30 days.

Ironwood Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of medicines for gastrointestinal disorders. Their business model involves discovering, developing, and marketing innovative treatments for conditions like irritable bowel syndrome and chronic constipation. They aim to achieve growth and profitability by leveraging their research capabilities and collaborating with strategic partners in the healthcare industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 78.188 mill.	$ 351.410 mill.	$ 0.880 mill.	88 mill.	-	Y/Y -22.98 %

Market Cap.	Revenues TTM	Net Income TTM
$ 78.188 mill.	$ 351.410 mill.	$ 0.880 mill.
Employees	Shares Outstanding	P/E
412	88 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -22.98 %	MRQ Y/Y - %

PHAT

$4.11

$-2.5800

-38.57%
Last 30 Days

PHAT

$4.11

$-2.5800

-38.57%

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc stock declined -38.57% during the last 30 days.

Phathom Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing treatments for gastrointestinal diseases. Their business model involves advancing their pipeline of drug candidates through research and development, and seeking regulatory approval for commercialization. By strategically targeting unmet medical needs in the gastrointestinal space, Phathom Pharmaceuticals aims to provide innovative solutions to improve patient outcomes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 265.620 mill.	$ 26.270 mill.	$ -339.445 mill.	65 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 265.620 mill.	$ 26.270 mill.	$ -339.445 mill.
Employees	Shares Outstanding	P/E
55	65 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

MTSR

$18.53

$-11.4800

-38.25%
Last 30 Days

MTSR

$18.53

$-11.4800

-38.25%

Metsera Inc

Metsera Inc stock went down -38.25% during the last 30 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 267.434 mill.	$ - mill.	$ -371.549 mill.	14 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 267.434 mill.	$ - mill.	$ -371.549 mill.
Employees	Shares Outstanding	P/E
-	14 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ALZN

$0.68

$-0.4200

-38.18%
Last 30 Days

ALZN

$0.68

$-0.4200

-38.18%

Alzamend Neuro Inc

Alzamend Neuro Inc shares dropped -38.18% during the last 30 days.

Alzamend Neuro Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for Alzheimer*s disease and other neurological disorders. Their business model revolves around conducting extensive research and clinical trials to develop groundbreaking treatments that address the underlying causes of these debilitating conditions. With a focus on creating value for patients, healthcare providers, and shareholders, they aim to bring effective therapies to market and improve the quality of life for those affected by neurodegenerative diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 3.752 mill.	$ - mill.	$ -4.227 mill.	6 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 3.752 mill.	$ - mill.	$ -4.227 mill.
Employees	Shares Outstanding	P/E
10	6 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

RAPT

$0.8786

$-0.5364

-37.91%
Last 30 Days

RAPT

$0.8786

$-0.5364

-37.91%

Rapt Therapeutics Inc

Rapt Therapeutics Inc stock declined -37.91% during the last 30 days.

Rapt Therapeutics Inc operates based on a business model that focuses on developing and commercializing transformative oral small molecules, known as immunomodulators. Their compounds target specific immune cell subsets within the body to provide potential therapeutic benefits in various diseases. By leveraging their expertise in immunology and small molecule drug design, Rapt strives to deliver innovative treatment options to patients in need.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 35.768 mill.	$ - mill.	$ -129.865 mill.	41 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 35.768 mill.	$ - mill.	$ -129.865 mill.
Employees	Shares Outstanding	P/E
42	41 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

CARM

$0.226

$-0.1318

-36.84%
Last 30 Days

CARM

$0.226

$-0.1318

-36.84%

Carisma Therapeutics Inc

Carisma Therapeutics Inc stock went down -36.84% during the last 30 days.

Carisma Therapeutics Inc*s business model focuses on developing novel CAR-Macrophage cell therapies to treat solid tumors. They aim to leverage their proprietary technology platform to engineer immune cells that can effectively target and destroy cancer cells, while also optimizing the manufacturing process for scalability and cost-effectiveness.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 9.362 mill.	$ 19.632 mill.	$ -60.477 mill.	41 mill.	-	Y/Y -14.83 %

Market Cap.	Revenues TTM	Net Income TTM
$ 9.362 mill.	$ 19.632 mill.	$ -60.477 mill.
Employees	Shares Outstanding	P/E
46	41 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -14.83 %	MRQ Y/Y - %

EWTX

$14.84

$-8.6000

-36.69%
Last 30 Days

EWTX

$14.84

$-8.6000

-36.69%

Edgewise Therapeutics inc

Edgewise Therapeutics Inc shares went down -36.69% during the last 30 days.

Edgewise Therapeutics Inc*s business model revolves around developing and commercializing small molecule therapies to treat rare muscle disorders.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1,369.507 mill.	$ - mill.	$ -133.813 mill.	92 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1,369.507 mill.	$ - mill.	$ -133.813 mill.
Employees	Shares Outstanding	P/E
21	92 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

TELO

$2.55

$-1.4700

-36.57%
Last 30 Days

TELO

$2.55

$-1.4700

-36.57%

Telomir Pharmaceuticals Inc

Telomir Pharmaceuticals Inc stock declined -36.57% during the last 30 days.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ - mill.	$ - mill.	$ -16.533 mill.	- mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ -16.533 mill.
Employees	Shares Outstanding	P/E
-	- mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ACRV

$1.64

$-0.8800

-34.92%
Last 30 Days

ACRV

$1.64

$-0.8800

-34.92%

Acrivon Therapeutics Inc

Acrivon Therapeutics Inc shares went down -34.92% during the last 30 days.

Acrivon Therapeutics Inc*s business model focuses on developing and commercializing innovative therapeutics in the healthcare industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 55.509 mill.	$ - mill.	$ -80.556 mill.	34 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 55.509 mill.	$ - mill.	$ -80.556 mill.
Employees	Shares Outstanding	P/E
43	34 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %